T1	condition 29 69	aromatase inhibitor-associated bone loss
T2	intervention 73 93	shugan jiangu recipe
T4	total-participants 348 350	38
T5	eligibility 351 443	patients of postmenopausal women with breast cancer, who received aromatase inhibitors (AIs)
T6	intervention-participants 483 485	21
T7	control 501 514	control group
T8	control-participants 516 518	17
T10	outcome 1249 1268	serum BALP and TRAP
T13	outcome 1430 1449	serum BALP and TRAP
T14	outcome 1552 1580	serum levels of BGP and BALP
T15	outcome 1606 1637	serum levels of CTX-II and TRAP
T16	outcome 1720 1744	No serious adverse event
T17	outcome 1783 1796	Bone fracture
T18	cv-bin-abs 1809 1812	one
T19	cv-bin-percent 1840 1844	5.8%
T3	outcome 1505 1530	lumbar and femur neck BMD
T12	outcome 1140 1166	BMD of L2-4 and femur neck
T20	outcome 1323 1349	BMD of L2-4 and femur neck
